Arrowhead Pharmaceuticals Inc (ARWR)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	166,263	225,258	245,998	267,743	278,338	243,231	249,939	263,418	144,424	138,288	107,638	89,123	79,841	87,993	123,653	138,974	163,593	168,796	136,758	94,788
Receivables	US$ in thousands	—	—	1,247	69,434	39,568	1,410	239	1,317	150	10,255	671	955	9,002	846	21,693	1,266	1,345	661	2,044	13,422
Receivables turnover		—	—	197.27	3.86	7.03	172.50	1,045.77	200.01	962.83	13.48	160.41	93.32	8.87	104.01	5.70	109.77	121.63	255.36	66.91	7.06

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $166,263K ÷ $—K
= —

Arrowhead Pharmaceuticals Inc.'s receivables turnover fluctuated significantly over the past eight quarters. In Q2 2022, the company had a very low receivables turnover of 1,045.77, implying that it collected its accounts receivable over a thousand times during that quarter. This may be an anomaly or misreporting. In Q3 2022, the turnover decreased to 172.50, which is still relatively high. The turnover further dropped in subsequent quarters, reaching a low of 3.93 in Q2 2023, indicating a slowdown in the collection of accounts receivable.

From Q3 2023 onwards, there was a significant improvement in the receivables turnover, reaching 205.46 in Q3 2023. This suggests that Arrowhead Pharmaceuticals Inc. started collecting its outstanding receivables more efficiently during this period. However, as the Q1 2024 data is not available, we cannot assess the most recent trend in receivables turnover.

Overall, Arrowhead Pharmaceuticals Inc. should continue monitoring its receivables turnover to ensure it is collecting outstanding payments efficiently and in a timely manner. fluctuations in the turnover rate may impact the company's liquidity and overall financial health.